Compare Shreyas Interm. with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 2.20% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -7.74 times
Flat results in Dec 25
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Commodity Chemicals
INR 55 Cr (Micro Cap)
NA (Loss Making)
23
0.00%
0.49
-8.03%
3.45
Total Returns (Price + Dividend) 
Shreyas Interm. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Shreyas Intermediates Ltd is Rated Strong Sell
Shreyas Intermediates Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 January 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 13 April 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
Shreyas Intermediates Ltd is Rated Strong Sell
Shreyas Intermediates Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 January 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis below is based on the company’s current fundamentals, returns, and financial metrics as of 02 April 2026, providing investors with the latest perspective on the stock’s position.
Read full news article Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Apr-2026 | Source : BSEIn terms of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 as amended we are submitting herewith a copy of the certificate received from- Skyline Financial Services Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended 31st March 2026. Kindly place the same on your record.
Submission Of Declaration Under Reg 31(4) Of SEBI (SAST) Regulations 2011
09-Apr-2026 | Source : BSEAttached is the Annual Disclosure received by the Company from its Promoter/Promoter Group under Regulation 31(4) of SEBI (SAST) Regulations 2011 as amended for the F.Y. ended 31.03.2026.
Closure of Trading Window
30-Mar-2026 | Source : BSEPursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and Shreyas IntermediateS limiteds Code of Conduct for Insiders the Trading Window for dealing in securities of the Company shall remain close for designated persons (as defined in the code) including their immediate relatives w.e.f. 01.04.2026 till 48 hours after the announcement of the Audited Financial Results for the quarter and year ended 31.03.026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
10.028
Held by 3 Schemes (0.0%)
Held by 1 FIIs (8.39%)
Kesar Petroproducts Limited (27.59%)
Krish Pharma Speciality Private Limited- Escrow Demat Accoun (24.7%)
7.82%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is -100.00% vs 64.08% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -62.50% vs 29.41% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 36.26% vs -8.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 23.62% vs 11.81% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -0.63% vs -0.64% in Mar 2024







